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Abstract 
Glioblastoma (GBM) is the most common malignant primary brain tumor. Receptor tyrosine 
kinase (RTK) pathways are frequently mutated in GBM, including alterations in the RTK Epidermal 
Growth Factor Receptor (EGFR). Moreover, EGFR variant III (EGFRvIII) is the most common 
activating mutation in GBM. Given its frequency, specificity, and role in promoting gliomagenesis, 
EGFR dysfunction is a prime target for drug treatment. However, multiple resistance mechanisms, 
such as co-occurrence of EGFRvIII and deletion of the tumor suppressor PTEN, prevent effective 
treatment via activation of alternate kinase pathways. To observe the differential kinase activation 
involved in EGFRvIII- and PTEN loss- driven gliomagenesis and identify potential kinase targets 
for dual therapy, we examined immortalized murine astrocytes derived from non-germline 
genetically engineered mouse models expressing four core genotypes: wild-type EGFR + wild-
type Pten (C), wild-type EGFR + Pten deletion (CP), EGFRvIII + wild-type Pten (CEv3), and 
EGFRvIII + Pten deletion (CEv3P). We used RNA sequencing and multiplexed inhibitor bead 
affinity chromatography and mass spectrometry (MIB-MS) to determine the baseline 
transcriptomes and kinomes of each genotype. We determined that cell lines exhibited genotype-
dependent baseline RNA expression and kinase activity as a result of EGFRvIII and/or Pten 
deletion relative to C astrocytes and across genotypes. We observed several differentially-
activated kinases that represent potential targets for dual treatment with EGFR TKI. We are 
currently examining changes in the kinome profile of each cell line after both acute and chronic 
treatment with tyrosine kinase inhibitors (TKI). These results will help define the kinase networks 
involved in tumor development and resistance and may aid in the identification of potential 
personalized combination therapy with EGFR TKI for GBM patients. 
Introduction 
 Glioblastoma (GBM), a grade IV astrocytoma, is the most common malignant primary 
brain tumor10. Current treatment includes surgical resection of the tumor and adjuvant radiation 
therapy plus the chemotherapeutic temozolomide13. However, survival rates for GBM remain 
extremely low with a five-year survival rate less than 10% and a recurrence rate of >90%10. 
Although GBM is diagnosed histologically and treated uniformly, it is genetically heterogeneous. 
The genes most frequently mutated in glioblastoma are involved primarily in three intracellular 
pathways: Retinoblastoma (RB), Receptor Tyrosine Kinase (RTK), and TP531. RTKs are 
regulators of intracellular signaling pathways that control multiple cellular functions, such as 
proliferation, metabolism, and survival6. Moreover, overexpression and mutation of RTKs has 
been shown to promote tumorigenesis across multiple cancer types8. Furthermore, these RTK 
amplifications and mutations are the most common targetable alterations in GBM, identified in 
66% of primary tumors6. 
 Alterations in Epidermal Growth Factor Receptor (EGFR) are the primary RTK lesions in 
GBM6. Activation of EGFR by Epidermal Growth Factor (EGF) results in dimerization and 
autophosphorylation, inducing various downstream signaling cascades that regulate multiple 
cellular functions, including proliferation, apoptosis, migration, and survival8. Mutations, 
rearrangements, and amplifications of EGFR are the most common genetic alteration in GBM, 
presenting in over 50% of tumors6. The most common EGFR mutation, EGFR variant III 
(EGFRvIII), is the most common activating mutation in glioblastoma and occurs in 25 – 33% of all 
tumors14. EGFRvIII lacks exons 2 – 7, resulting in a truncated extracellular domain, which 
prevents the receptor from binding to the ligand6. This causes constitutive activation of 
downstream signaling, commonly activating the phosphatidylinositol 3-kinase (PI3K) pathway, 
resulting in ligand-independent increases in proliferation and survival and promotion of 
gliomagenesis4,14. 
 Given the frequency of occurrence and role in promoting GBM tumorigenesis, EGFR 
mutations are a prime target for drug treatment with Tyrosine Kinase Inhibitors (TKI)5. However, 
despite the number of available EGFR inhibitors, multiple resistance mechanisms prevent 
effective single-agent treatment, with only 10 – 20% of patients exhibiting response to EGFR TKI8. 
One such mechanism involves the co-existence of mutations in downstream effectors or alternate 
activation of other RTK pathways; moreover, there is a frequent co-occurrence of RTK mutation 
and PTEN deletion in GBM6. PTEN, the phosphatase and tensin homolog deleted on 
chromosome 10, is a tumor suppressor that negatively regulates PI3K signaling by 
dephosphorylating phosphatidylinositol-3,4,5-triphosphate (PIP3), and also performs multiple 
other tumor suppressor functions5. PTEN is frequently lost or mutated in GBM at a rate of 40%; 
this deletion maintains signaling, which in effect promotes tumorigenesis5,6. Though presence of 
wild-type PTEN is associated with sensitivity to EGFR TKI in cell lines harboring EGFRvIII, PTEN 
deletion confers resistance when expressed with EGFRvIII as a result of constitutive activation of 
downstream pathways5,8. The kinase networks involved in EGFRvIII- and PTEN loss- driven 
pathogenesis and resistance have not yet been determined.  
We examined murine astrocytes immortalized via deletion of cyclin-dependent kinase 
inhibitor 2A (Cdkn2a), which occurs in approximately 60% of GBM and is also frequently mutated 
alongside PTEN deletion and EGFRvIII6. These astrocytes were derived from non-germline 
genetically engineered mouse models expressing four core genotypes: wild-type EGFR + wild-
type Pten (C), wild-type EGFR + Pten deletion (CP), EGFRvIII + wild-type Pten (CEv3), and 
EGFRvIII + Pten deletion (CEv3P). To investigate EGFRvIII- and PTEN loss- driven kinase 
activation and identify potential targets for drug treatment, we used RNA sequencing (RNA-seq) 
and multiplexed inhibitor beads/mass spectrometry (MIB-MS) to determine the baseline kinase 
expression profile (transcriptome) and activity profile (kinome) of each genotype. We determined 
that EGFR and Pten mutation status influenced the transcriptomes and kinomes of Cdkn2a 
(Ink4a/Arf)-null cell lines. These core genotypes exhibited differential RNA expression and kinase 
activity levels relative to astrocytes expressing wild-type EGFR and wild-type Pten, identifying 
several potentially attractive target kinases for dual therapy with EGFR TKI.  
Methods  
Astrocyte culture. Ink4a/Arf-null murine astrocytes were derived from Cdkn2a-null genetically 
engineered mice.  Non-germline genetically engineered mouse (nGEM) models were generated 
by expressing either wild-type EGFR + wild-type PTEN, wild-type EGFR + PTEN deletion, 
EGFRvIII + wild-type PTEN, or EGFRvIII + PTEN deletion in these astrocytes. All cell lines were 
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine 
serum (FBS) and 1% penicillin/streptomycin (P/S) and maintained at 37°C and 5% CO2. 
RNA-sequencing. Total RNA from samples of each cell line was purified using the RNeasy 
Plus Mini Kit (Qiagen). RNA-sequencing was performed as previously described3,12. Briefly, 
poly(A) RNA was captured from 2 g total isolated RNA with magnetic oligo-dT mRNA capture 
beads and beads were resuspended in 1X Fragment, Prime and Elute Buffer. In a thermocycler, 
mRNA was fragmented for 7 minutes at 94C for a desired mean library fragment size of ~275 
bp. The fragmented RNA was eluted and incubated with primers to synthesize first strand cDNA 
via reverse transcriptase. Double-stranded cDNA was synthesized, and A-tailing reaction was 
then performed. Adapters were ligated to dscDNA fragments, and library was amplified by PCR. 
Sample quality and fragment size were checked using Agilent 2200 TapeStation. Library was 
sequenced with an Illumina NextSeq-500, and analysis was performed as previously 
described3,12. 
Multiplexed inhibitor bead affinity chromatography/mass spectrometry. Cells were 
harvested for baseline MIB-MS analysis. Cells were lysed in MIB lysis buffer [50 mM HEPES (pH 
7.5), 150 mM NaCl, 0.5% Triton X-100, 1 mM EDTA, 1 mM EGTA, 10 mM NaF, 2.5 mM NaVO4, 
protease inhibitor cocktail (Roche Applied Science, Penzberg, Germany), 500 μL phosphatase 
inhibitor cocktail 2 (Sigma-Aldrich, St. Louis, MO), 500 μL phosphatase inhibitor 3 (Sigma-Aldrich, 
St. Louis, MO)] and incubated on ice for 10 minutes. Lysates were sonicated 3 x 15 seconds and 
centrifuged at maximum speed (19,090 rpm) for 10 minutes at 4°C. Supernatant was filtered 
through 0.2 μm filter. BCA assay was conducted to equalize the input protein to 5 mg across 
samples. Lysates were brought to 1 M NaCl using Ambion 5 M NaCl and multiplexed inhibitor 
(PP58-, Purvalanol B-, UNC-21474-, Buparlisib-, and VI-16832-coated) beads were mixed in 
equal volumes and loaded into columns. MIB columns were washed with 2 mL high-salt MIB wash 
buffer [50 mM HEPES (pH 7.5), 1 M NaCl, 0.5% Triton X-100, 1 mM EDTA, 1 mM EGTA], and 
lysates were passed through the columns. MIB columns were washed with 5 mL high-salt MIB 
wash buffer, 5 mL low-salt buffer [50 mM HEPES (pH 7.5), 150 mM NaCl, 0.5% Triton X-100, 1 
mM EDTA, 1 mM EGTA], and then 500 μL 0.1% SDS in low-salt wash buffer. Twice, 500 μL MIB 
elution buffer [0.5% SDS, 1% β-mercarptoethanol, 0.1 M Tris-HCl (pH 6.8), LC-MS grade water] 
was added and eluate was collected after boiling columns for 15 minutes. Samples were treated 
with dithiothreitol (DTT) and iodoacetamide to reduce and alkylate the kinases and were then 
concentrated by filtration. Proteins were precipitated after methanol/chloroform extraction and 
incubated in 5 μL trypsin overnight at 37°C to digest the proteins. Samples were then extracted 
using ethyl acetate and cleaned using C-18 PepClean spin columns (Pierce Biotechnology, 
Rockford, IL). Mass spectrometry analysis was performed as previously described3,12. 
Results 
EGFRvIII and PTEN loss have been implicated in GBM tumorigenesis, but effects of these 
mutations on kinome activation that promotes this process have not yet been determined. We 
investigated this issue in vitro by using RNA-seq and MIB-MS to examine the baseline 
transcriptomes and kinomes of immortalized cell lines harboring either EGFRvIII, Pten deletion, 
or both, in comparison to wild-type EGFR and wild-type Pten astrocytes. 
RNA-seq was performed to define the baseline kinase expression profile and multiplexed 
inhibitor bead affinity chromatography/mass spectrometry (MIB-MS) was used to determine the 
baseline kinase activity profile for each cell line: C, CP, CEv3, and CEv3P. To assess the 
similarities and differences between the transcriptomes and kinomes of each cell line, principal 
component analysis (PCA) was performed. PC1 and PC2 were plotted to analyze common and 
unique variants between cell lines and between replicates for each line. 
 
 
  
Based on principal component analysis, samples appear to cluster based on EGFRvIII 
status (PC1) and Pten deletion status (PC2). Replicates for each cell line cluster together 
according to cell line, validating the consistency between replicates. Loss of Pten blunts the effect 
of EGFR versus EGFRvIII, as shown by the decrease in variation of PC1 between CEv3P and 
CP compared to the difference between CEv3 and C. Additionally, the relative relationships 
between samples are similar between kinome analysis (Figure 1A) and transcriptome analysis 
(Figure 1B); thus, the results are consistent between MIB-MS and RNA-seq. Overall, PCA 
Figure 1. EGFRvIII and Pten deletion mutations cluster according to kinomes and transcriptomes. 
Principal Component Analysis was performed for kinome (A) and transcriptome (B) analysis, where Principal 
Component 1 (PC1) clusters by EGFR status and Principal Component 2 (PC2) clusters by Pten status. 
 
indicates that EGFRvIII and Pten deletion mutation statuses influence kinase expression and 
activity levels of these cell lines.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. The four core genotypes result in differential kinase activity and RNA expression. Results from 
RNA-seq and MIB-MS analysis were plotted for each cell line relative to wild-type (A-C) and relative to the 
alternate genotypes (D-F). Differential RNA expression and kinase activity (closed circles) and differential 
kinase activity (open circles) shown between cell lines in terms of fold change (FDR Q<0.001). 
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Cell lines were harvested and analyzed by RNA sequencing and MIB-MS to determine the 
transcriptome and kinome profiles for all cell lines. RNA-seq determines the level of gene 
expression, and MIB-binding represents a function of kinase activation – increased binding 
indicates increased kinase activation, whereas decreased binding indicates decreased kinase 
activity level. RNA expression and kinase activity levels were plotted to compare the profile of 
each cell line to wild-type (C), and additionally graphed relative to each of the other genotypes 
separately. Differential core genotypes expressing EGFRvIII and/or Pten deletion resulted in 
varying fold-changes in kinase activity and RNA expression levels between cell lines (Figure 2).  
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There was increased activity of a total of 38 kinases and decreased activity of a total of 29 
kinases relative to Ink4a/Arf-null astrocytes expressing wild-type EGFR and wild-type Pten (C) 
(Figure 3A, 3B). The kinases with upregulated activity across all three cell lines were Cdk19, 
Cdk15, Mapk10, and Prkaa2 compared to astrocytes harboring both wild-type EGFR and wild-
type Pten. The kinases with downregulated activity across all three cell lines relative to C 
astrocytes were Prkg1, Prkg2, Ptk2b, Ripk3, Syk, Epha1, Ephb6, Fes, Frk, and Nme4.  
There was an increase in activity of Ddr1, Ephb2, and Tnik solely in CP relative to C 
astrocytes, presumably as a result of Pten loss in CP astrocytes. Also solely in CP, there was 
decreased activity of kinases Mark1 and Yes1, suggesting the loss of Pten influenced 
downregulation of these kinases. The kinases upregulated in both Pten-mutant cell lines, CP and 
Figure 3. Cell lines exhibit differential kinase activity. Kinases with upregulated activity (A) or downregulated 
activity (B) compared to activity level in C astrocytes. 
B 
CEv3P, relative to C astrocytes were Akt1 and Epha5. There was a decrease in activity of kinases 
Agphd1, Cdk18, Lyn, and Mapk6 in these cell lines. 
Relative to C astrocytes, CEv3 singularly exhibited increased activity of Acvr1b, Adck4, 
Bmx, Cdk17, Cdk4, Ephb4, Em1, Ikbkb, Insr, Ipmk, Nek2, Pask, Rps6ka3, Rps6ka6, and Smg1, 
which suggests these kinases were upregulated as a result of EGFRvIII expression. CEv3 also 
specifically exhibited decreased activity of Acvr1, Ephb2, Ephb3, Pdgfrb, and Stk10 compared to 
C, suggesting EGFRvIII influenced the reduction in activity of these kinases. 
CEv3P exclusively exhibited increased kinase activity of Pck2, Pfkl, Pip4k2c, and Stk35, 
and decreased activity of Bmpr1a, Fgfr2, Rps6ka6, and Tgfbr2, suggesting that the combination 
of EGFRvIII and Pten deletion possibly cooperates to influence the activation of these kinases 
that were not differentially-activated in cell lines harboring either only EGFRvIII or Pten loss. 
Additionally, notably fewer kinases were activated in CEv3P compared to CEv3, indicating that 
deletion of Pten blunts the effect of CEv3, consistent with principal component analysis. 
In both EGFR-mutant cell lines, CEv3P and CEv3, there was increased activity of Acvr2a, 
Cdk5, Chka, Chkb, Chuk, Egfr, Rps6ka1, and Stk3 relative to C. Both CEv3P and CEv3, but not 
CP, exhibited downregulated activity of Camk2a, Epha4, and Flt4, suggesting the presence of 
EGFRvIII affected the decrease in activity of these kinases. 
These results show that EGFRvIII and Pten deletion mutations influence genotype-
dependent kinase expression and activity levels when compared to astrocytes harboring wild-
type EGFR and wild-type Pten.  
Discussion  
Genomic sequencing of GBM identifies EGFRvIII and PTEN deletion in a large percentage 
of tumors, and these mutations have been shown to promote tumorigenesis in vivo5,6,14. Though 
EGFR mutation has emerged as an attractive target for drug treatment, multiple resistance 
mechanisms have been implicated in affecting the responses of EGFR-mutant cell lines to single-
agent EGFR tyrosine kinase inhibitor treatment in GBM8. Consequently, determining the profiles 
of these cell lines will aid in the identification of potential kinase targets for dual treatment with 
EGFR TKI for a more effective precision therapy approach. Herein, we investigated the baseline 
transcriptome and kinome states of four core genotypes expressing EGFRvIII, Pten deletion, or 
both, in order to aid in determining the differential kinase expression and activation involved in 
EGFRvIII- and Pten loss- driven gliomagenesis. Principal component analysis showed that 
EGFRvIII and Pten deletion influenced the transcriptome and kinome profiles of each cell line. 
RNA-seq and MIB-MS showed that EGFRvIII and/or Pten deletion influences differential baseline 
RNA expression and baseline kinase activity of the four core genotypes relative to wild-type and 
across genotypes.  
There was a general increase in activity of kinases involved in the regulation of cell 
proliferation, survival, signal transduction, and metabolism. Cyclin dependent kinases Cdk19 and 
Cdk15 were upregulated across all cell lines except C, consistent with their role in proliferation. 
In addition, there was increased activity of Mapk10 across all cell lines relative to C, as well as 
Rps6ka3 in CEv3, indicating a possible increase in the activity of MAPK/JNK and MAPK/ERK 
pathways, which also promote increased growth and migration of cells. Other kinases involved in 
the regulation of cell metabolism showed increased activity, including Prkaa2 in all cell lines 
except C and Pfkl in CEv3P. Additionally, there was upregulated activity of multiple other RTKs, 
including Ddr1, Ephb2, Insr, Ephb4, and Epha5 in various cell lines. In EGFR-mutant cell lines, 
there was upregulation of EGFR activity, which is consistent with the effects of EGFRvIII, and in 
Pten-mutant cell lines, there was increased activity of Akt1, indicating increased stimulation of the 
PI3K pathway, which is consistent with the effects of Pten loss. 
There was a general decrease in activity of kinases with proposed tumor suppressor 
functions, including Ripk3, Syk, Frk, and Nme4, across all cell lines except C. Other kinases with 
roles in growth inhibition, including Tgfbr2 in CEv3P and Lyn in CP and CEv3P, were 
downregulated as well. Decreased activity of these kinases indicates a decrease in negative 
regulation of proliferation in EGFR- and/or Pten-mutant cell lines compared to wild-type. Since 
MIB-binding represents a function of kinase activation, we will perform immunoblots for phospho 
and non-phospho targets to measure downstream pathway signaling for the notable differentially-
activated kinases.  
Though tumor suppressor proteins are difficult to target in cancer therapy, the observed      
overactive kinases may serve as attractive targets for combination drug treatment with EGFR TKI. 
Specifically, Ephb4 (upregulated in CEv3) and Epha5 (upregulated in both CP and CEv3P) are 
Ephrin (Eph) receptors of the RTK family. Eph receptor tyrosine kinases have been implicated in 
cancer growth and Ephb4 and Epha5 are altered in 1.4% and 1.1% of GBM, respectively, which 
makes these kinases potentially attractive for targeted treatment of EGFR-mutant GBM with and 
without PTEN2,7,9,11. Also upregulated were Rps6ka3 in CEv3 and Rps6ka1 in both CEv3 and 
CEv3P, which phosphorylate targets in the MAPK/ERK pathway9,11. Since this pathway stimulates 
processes such as cell proliferation and survival, targeting these two kinases could be beneficial 
in treating EGFRvIII-expressing GBM with or without PTEN. Ikbkb and Chuk were hyperactive in 
CEv3 and both CEv3 and CEv3P, respectively; these kinases are involved in the activation of NF-
kappa-B, which leads to cell growth and prevention of apoptosis9,11. Thus, these kinases could 
also be potential targets for treatment of patients with tumors harboring EGFRvIII with and without 
PTEN. A potential target in cell lines expressing EGFRvIII and wild-type Pten is Nek2, a cell-cycle 
regulator which has been associated with tumorigenesis and is altered in 1.1% of GBM2,7,9,11,. 
Finally, Akt1 of the PI3K pathway was upregulated in both CP and CEv3P and is also altered in 
1.4% of GBM2,7. Since PI3K signaling promotes cell growth, targeting Akt1 could be effective for 
Pten-mutant tumors that lack negative regulation of this pathway. Overall, these results from 
kinome profiling identify the genotype-dependent kinase activation involved in processes behind 
EGFRvIII- and Pten loss- driven tumorigenesis, and identify several preliminary kinase targets for 
future combination therapy with EGFR TKI.  
 Though baseline kinome profiling identifies potential kinase targets for dual treatment, 
resistance may still occur in response to EGFR inhibition as a result of dynamic reprogramming 
of the kinome. Subsequently, observing the kinases that are differentially-activated in direct 
response to drug treatment may identify targets that more accurately predict effective dual 
therapy; targeting these kinases would ideally inhibit the activation of additional pathways that 
contribute to EGFR TKI resistance. In order to investigate the role of EGFRvIII and Pten deletion 
in adaptive kinome reprogramming and resistance, we will perform RNA-seq and MIB-MS for 
these cell lines after one-time treatment with 3 μM afatinib, an EGFR TKI. Compared to the 
baseline kinome state, we would expect significant changes in MIB-binding, and thus kinase 
activity, of alternate kinase pathways across all cell lines in response to drug treatment, which is 
indicative of kinome response to TKI. We are also culturing these astrocytes in media with either 
of two EGFR TKI, gefitinib or erlotinib, in order to investigate the response of these resistant cell 
lines after chronic treatment. Whereas determining the response of cell lines after immediate 
treatment shows adaptive resistance to EGFR inhibition, we will perform RNA-seq and MIB-MS 
for cell lines grown in long-term culture with low-dose gefitinib or erlotinib to identify the kinase 
networks involved in acquired resistance. These results may be more applicable to patient care, 
as acquired resistance could arise during chronic drug treatment. Dynamic kinome profiling will 
aid in determining the kinase networks involved in both acute and acquired resistance 
mechanisms, which will be relevant to developing personalized combination treatments for 
genome-sequenced GBM patients. 
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